Register entryShortage reported
- Registered sites
- 0
- Active NDC listings
- 81
- Labeller names
- 2
- Live patents
- 21
- Shortage listings
- 15
- Countries
- 0
Alert
Drug shortage listings
15| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Rifampin InjectionAnti-Infective | Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Current | Unavailable | 17 Feb 202118 Sept 2026 |
| Glyburide TabletEndocrinology/Metabolism | Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01) | To Be Discontinued | - | 10 Aug 202610 Aug 2026 |
| Glyburide TabletEndocrinology/Metabolism | Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53) | To Be Discontinued | - | 10 Aug 202610 Aug 2026 |
| Glyburide TabletEndocrinology/Metabolism | Diabeta, Tablet, 5 mg (NDC 0093-9364-01) | To Be Discontinued | - | 10 Aug 202610 Aug 2026 |
| Glyburide TabletEndocrinology/Metabolism | Diabeta, Tablet, 5 mg (NDC 0093-9364-10) | To Be Discontinued | - | 10 Aug 202610 Aug 2026 |
| Rifapentine Tablet, Film CoatedAnti-Infective | Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24) | Resolved | - | 25 Mar 20206 Aug 2026 |
| Leflunomide TabletRheumatology | Leflunomide, Tablet, 10 mg (NDC 0955-1735-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Leflunomide TabletRheumatology | Arava, Tablet, 10 mg (NDC 0088-2160-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Leflunomide TabletRheumatology | Arava, Tablet, 20 mg (NDC 0088-2161-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Leflunomide TabletRheumatology | Arava, Tablet, 100 mg (NDC 0088-2162-33) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Leflunomide TabletRheumatology | Leflunomide, Tablet, 20 mg (NDC 0955-1737-30) | To Be Discontinued | - | 8 Jun 20268 Jun 2026 |
| Rifampin InjectionAnti-Infective | Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | To Be Discontinued | - | 20 Apr 202620 Apr 2026 |
| Doxercalciferol InjectionEndocrinology/Metabolism | Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1) | To Be Discontinued | - | 10 Dec 202510 Dec 2025 |
| Doxercalciferol InjectionEndocrinology/Metabolism | Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1) | To Be Discontinued | - | 10 Dec 202510 Dec 2025 |
| Doxercalciferol InjectionEndocrinology/Metabolism | Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1) | To Be Discontinued | - | 10 Dec 202510 Dec 2025 |
Catalogue
Drug listings by form and route
8181 active NDC listings: 81 human prescription drug. By marketing category: NDA 34, BLA 31, NDA AUTHORIZED GENERIC 15, UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE 1.
| Dosage form | NDCs |
|---|---|
| injection | 26 |
| injection, solution | 26 |
| tablet, film coated | 15 |
| injection, solution, concentrate | 5 |
| kit | 4 |
| powder, for suspension | 2 |
| solution, concentrate | 2 |
| tablet | 1 |
| Route | NDCs |
|---|---|
| subcutaneous | 50 |
| oral | 18 |
| intravenous | 16 |
| Labeller name on the listing | NDCs |
|---|---|
| sanofi-aventis u.s. llc | 69 |
| sanofi-aventis u.s. llc | 12 |
Exclusivity
Patents and exclusivities
21| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 6794410*PED | AUBAGIOteriflunomide | use | Mar 2027 |
| 8410167 | MULTAQdronedarone hydrochloride | use | Apr 2029 |
| 9107900 | MULTAQdronedarone hydrochloride | use | Apr 2029 |
| 8802735 | AUBAGIOteriflunomide | product | Sept 2030 |
| 10583110 | JEVTANA KITcabazitaxel | use | Oct 2030 |
| 10716777 | JEVTANA KITcabazitaxel | use | Oct 2030 |
| 12453712 | JEVTANA KITcabazitaxel | use | Oct 2030 |
| 8927592 | JEVTANA KITcabazitaxel | use | Oct 2030 |
| 8802735*PED | AUBAGIOteriflunomide | use | Mar 2031 |
| 10583110*PED | JEVTANA KITcabazitaxel | use | Apr 2031 |
| 10716777*PED | JEVTANA KITcabazitaxel | use | Apr 2031 |
| 12453712*PED | JEVTANA KITcabazitaxel | use | Apr 2031 |
| 8927592*PED | JEVTANA KITcabazitaxel | use | Apr 2031 |
| 8602215 | MULTAQdronedarone hydrochloride | use | Jun 2031 |
| 9186346 | AUBAGIOteriflunomide | use | Feb 2034 |
| 9186346*PED | AUBAGIOteriflunomide | use | Aug 2034 |
Catalogue
Marketed products
83Showing 81 of 83.
| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ADMELOG | insulin lispro | injection, solution, intravenous, subcutaneous | 0024-5924BLA |
| ADMELOG | insulin lispro | injection, solution, subcutaneous | 0024-5925BLA |
| ADMELOG | insulin lispro | injection, solution, intravenous, subcutaneous | 0024-5926BLA |
| Ambien | zolpidem tartrate | tablet, film coated, oral | 0024-5401NDA |
| Apidra | insulin glulisine | injection, solution, intravenous, subcutaneous | 0088-2500BLA |
| Apidra SoloStar | insulin glulisine | injection, solution, subcutaneous | 0088-2502BLA |
| Arava | leflunomide | tablet, film coated, oral | 0088-2160NDA |
| Arava | leflunomide | tablet, film coated, oral | 0088-2161NDA |
| Arava | leflunomide | tablet, film coated, oral | 0088-2162NDA |
| Avalide | irbesartan and hydrochlorothiazide | tablet, film coated, oral | 0024-5855NDA |
| Avalide | irbesartan and hydrochlorothiazide | tablet, film coated, oral | 0024-5856NDA |
| Avapro | irbesartan | tablet, film coated, oral | 0024-5851NDA |
| Avapro | irbesartan | tablet, film coated, oral | 0024-5852NDA |
| Docetaxel | Docetaxel | injection, solution, concentrate, intravenous | 0955-1020NDA AUTHORIZED GENERIC |
| Docetaxel | Docetaxel | injection, solution, concentrate, intravenous | 0955-1021NDA AUTHORIZED GENERIC |
| Docetaxel | Docetaxel | injection, solution, concentrate, intravenous | 0955-1022NDA AUTHORIZED GENERIC |
| Dupixent | Dupilumab | injection, solution, subcutaneous | 0024-5914BLA |
| Dupixent | Dupilumab | injection, solution, subcutaneous | 0024-5915BLA |
| Dupixent | Dupilumab | injection, solution, subcutaneous | 0024-5918BLA |
| Dupixent | Dupilumab | injection, solution, subcutaneous | 0024-5919BLA |
| Elitek | rasburicase | kit | 0024-5150BLA |
| Elitek | rasburicase | kit | 0024-5151BLA |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1003NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1004NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1006NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1008NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1010NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1012NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1015NDA AUTHORIZED GENERIC |
| Enoxaparin sodium | enoxaparin sodium | injection, subcutaneous | 0955-1016NDA AUTHORIZED GENERIC |
| Ferrlecit | sodium ferric gluconate complex | injection, intravenous | 0024-2792NDA |
| Ferrlecit | sodium ferric gluconate complex | injection, intravenous | 0024-2794NDA |
| Fexinidazole | Fexinidazole | tablet, oral | 0024-4512NDA |
| Insulin glargine U-300 | insulin glargine | injection, solution, subcutaneous | 0955-3900BLA |
| Insulin glargine U-300 Max | insulin glargine | injection, solution, subcutaneous | 0955-2900BLA |
| Jevtana | cabazitaxel | kit | 0024-5824NDA |
| KEVZARA | sarilumab | injection, solution, subcutaneous | 0024-5908BLA |
| KEVZARA | sarilumab | injection, solution, subcutaneous | 0024-5910BLA |
| KEVZARA | sarilumab | injection, solution, subcutaneous | 0024-5920BLA |
| KEVZARA | sarilumab | injection, solution, subcutaneous | 0024-5922BLA |
| Lantus | insulin glargine | injection, solution, subcutaneous | 0088-2220BLA |
| Lantus Solostar | insulin glargine | injection, solution, subcutaneous | 0088-2219BLA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-0620NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-0621NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-0622NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-0623NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-0624NDA |
| Lovenox | enoxaparin sodium | injection, intravenous, subcutaneous | 0075-0626NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-2912NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-2915NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8013NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8014NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8016NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8018NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8020NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8022NDA |
| Lovenox | enoxaparin sodium | injection, subcutaneous | 0075-8025NDA |
| Lovenox | enoxaparin sodium | injection, intravenous, subcutaneous | 0075-8030NDA |
| MERILOG | insulin aspart-szjj | injection, solution, intravenous, subcutaneous | 0024-5927BLA |
| MERILOG | insulin aspart-szjj | injection, solution, intravenous, subcutaneous | 0024-5928BLA |
| Mozobil | PLERIXAFOR | injection, solution, subcutaneous | 0024-5862NDA |
| Multaq | Dronedarone | tablet, film coated, oral | 0024-4142NDA |
| Plavix | clopidogrel | tablet, film coated, oral | 0024-1171NDA |
| Plavix | clopidogrel | tablet, film coated, oral | 0024-1332NDA |
| Praluent | alirocumab | injection, solution, subcutaneous | 0024-5901BLA |
| Praluent | alirocumab | injection, solution, subcutaneous | 0024-5902BLA |
| Priftin | rifapentine | tablet, film coated, oral | 0088-2102NDA |
| Primaquine Phosphate | Primaquine Phosphate | tablet, film coated, oral | 0024-1596NDA |
| Rifadin | rifampicin | kit | 0068-0660UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Sarclisa | isatuximab | injection, solution, concentrate, intravenous | 0024-0654BLA |
| Sarclisa | isatuximab | injection, solution, concentrate, intravenous | 0024-0656BLA |
| Sarclisa Escena | isatuximab-irfc | injection, solution, subcutaneous | 0024-0674BLA |
| Sevelamer Carbonate | Sevelamer Carbonate | tablet, film coated, oral | 0955-1050NDA AUTHORIZED GENERIC |
| Sevelamer Carbonate | Sevelamer Carbonate | powder, for suspension, oral | 0955-1052NDA AUTHORIZED GENERIC |
| Sevelamer Carbonate | Sevelamer Carbonate | powder, for suspension, oral | 0955-1054NDA AUTHORIZED GENERIC |
| Sevelamer Carbonate | Sevelamer Carbonate | tablet, film coated, oral | 0955-1057NDA AUTHORIZED GENERIC |
| Soliqua 100/33 | insulin glargine and lixisenatide | injection, solution, subcutaneous | 0024-5761BLA |
| TOUJEO | insulin glargine | injection, solution, subcutaneous | 0024-5869BLA |
| TOUJEO Max | insulin glargine | injection, solution, subcutaneous | 0024-5871BLA |
| ZALTRAP | ziv-aflibercept | solution, concentrate, intravenous | 0024-5840BLA |
| ZALTRAP | ziv-aflibercept | solution, concentrate, intravenous | 0024-5841BLA |
Compare
Other companies listing enoxaparin sodium
- Cardinal Health 418, Inc.34 sites · 833 NDC
- Fresenius Kabi USA, LLC6 sites · 561 NDC
- Amphastar France Pharmaceuticals2 sites · 23 NDC
- HEBEI CHANGSHAN BIOCHEMICAL PHARMACEUTICAL CO.,LTD.1 site · 9 NDC
- BluePoint Laboratories Inc.0 sites · 352 NDC
- BE Pharmaceuticals Inc.0 sites · 29 NDC
Enquiry
Common questions
- Is sanofi-aventis U.S. LLC FDA approved?
- sanofi-aventis U.S. LLC holds no registered establishment of its own; 83 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does sanofi-aventis U.S. LLC make?
- 83 products are listed under sanofi-aventis U.S. LLC in the openFDA NDC Directory, most often as injection; injection, solution; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
- Are any sanofi-aventis U.S. LLC products in shortage?
- 1 presentation is currently listed in the FDA drug shortage database under sanofi-aventis U.S. LLC, covering Rifampin Injection.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.